Subjects ” Alzheimer’s and dementia
HealthDay News – The controversial approval of a new drug for Alzheimer’s disease by the US Food and Drug Administration and the high price are currently under investigation by two committees of the House of Representatives.
“We have serious concerns about the high price of Biogen’s new Alzheimer’s drug, Aduhelm, and the process that led to its approval, despite questions about the drug’s clinical utility,” House Democrats Carolyn Maloney and Frank Pallone Jr. said in a statement of the Oversight Committee and Reform and Energy and Trade Committee, CNN reported. “We strongly support innovative treatments to help millions of Americans with Alzheimer’s disease, but Aduhelm’s approval and $ 56,000 annual price tag will have wider implications for seniors, providers, and taxpayers who require scrutiny. “
Although an FDA advisory committee concluded that there wasn’t enough evidence that Aduhelm (aducanumab) was effective, the agency approved the drug earlier this month, CNN reported. Three of the advisory committee members resigned after the FDA approved the drug.
Continue reading
Most of the FDA reviewers who evaluated the company’s applications for aducanumab recommended approval, CNN reported. “Alzheimer’s disease is a serious disease and, unlike other approved therapies, aducanumab targets an underlying, fundamental and defining pathophysiological characteristic of the disease with the potential to alter the inevitable and unstoppable progression of the disease,” the reviewers said.
The drug is infused once every four weeks. The wholesale cost is approximately $ 4,312 per infusion.
CNN article
Subjects:
Alzheimer’s disease and dementia dementia treatments
Would you like to read more?
Please log in or register first to view this content.
Login Register
to open
Next post in Alzheimer’s and Dementia
Shut down
For more information on the House of Representatives committees investigating the approval of new drugs for Alzheimer’s disease close
Loading… 
For more information on the House of Representatives committees investigating the approval of new drugs for Alzheimer’s disease close
Loading…
For more information on the House of Representatives committees investigating the approval of new drugs for Alzheimer’s disease close
Loading…
For more information on the House of Representatives committees investigating the approval of new drugs for Alzheimer’s disease close
Loading…
Would you like to see more content from Neurology Advisor?
Register now for free to access unlimited clinical news with personalized daily tips for you, Full-length features, case studies, conference coverage, and more.
{{login-button}} {{register-button}}
Would you like to read more?
Please log in or register first to view this content.
Login Register
